Articles tagged "Heart transplant patients"

2020 American Transplant Congress
Impact of Worsening Renal Function While Waiting for Heart Transplantation
A. Kumar¹, C. P. Thomas²
¹Internal Medicine, University of Vermont, Burlington, VT, ²Internal Medicine, University of Iowa, Iowa City, IA
*Purpose: Pre transplant renal function has been shown to be a strong predictor of long term renal as well as patient survival in heart transplant…
2020 American Transplant Congress
Outcomes of Hiv-Positive Patients Post-Cardiac Transplantation
G. S. Liu¹, A. M. Wolfson², A. D. Salimbangon³, R. R. Chand⁴, P. Banankhah¹, J. Nattiv¹, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, E. C. DePasquale¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³UCLA Medical Center, Los Angeles, CA, ⁴Harbor-UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth-Israel Medical Center, Newark, NJ
*Purpose: Human immunodeficiency virus (HIV) infection is no longer an absolute contraindication to heart transplantation (HT) in many HT centers, but long-term post-HT outcomes of…
2020 American Transplant Congress
UNOS Registry Myocarditis Heart Transplantation Outcome
J. P. Li¹, P. Kingsford¹, S. Nuno¹, D. Miklin¹, G. Liu², J. Rahman², K. Pandya², C. Lum³, P. Banankhah², P. Genyk¹, D. Vucicevic⁴, A. Wolfson⁵, R. Chand⁶, K. Yang¹, S. Shah¹, A. Kiankhooy⁷, J. Nattiv², S. Hashmi¹, J. Pizula¹, A. Lee¹, M. Fong², L. Grazette², E. C. DePasquale², A. S. Vaidya²
¹Internal Medicine, Keck Medicine of USC, Los Angeles, CA, ²Cardiology, Keck Medicine of USC, Los Angeles, CA, ³Internal Medicine, The Queen's Medical Center, Honolulu, HI, ⁴Cardiology, Newark Beth-Israel Medical Center, Newark, NJ, ⁵Cardiology, University of Arizona Sarver Heart Center, Tuscon, AZ, ⁶Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, ⁷Cardiothoracic Surgery, Keck Medicine of USC, Los Angeles, CA
*Purpose: Hospitalized myocarditis patients have a variable course that can require heart transplantation at a rate of about 3-4%. We sought to evaluate the post-transplant…
2020 American Transplant Congress
Survival with Post-Transplant Diabetes Mellitus is Worse after Heart Transplantation
K. Y. Feng¹, E. Henricksen², Y. Moayedi³, R. Lee², J. Han¹, S. Purewal¹, A. Puing¹, M. Basina¹, J. J. Teuteberg¹, K. K. Khush¹
¹Medicine, Stanford University, Palo Alto, CA, ²Pharmacy, Stanford University, Palo Alto, CA, ³Cardiology, University Health Network, Toronto, ON, Canada
*Purpose: An increasing number of patients undergoing heart transplantation (HTx) have diabetes mellitus (DM). However, there is limited data on clinical outcomes after HTx in…
2020 American Transplant Congress
Comparison of Outcomes between Patients Bridged to Heart Transplantation with ECMO versus Those Not Bridged with ECMO During the Years 1985 to 2019
D. J. Miklin¹, A. D. Salimbangon², G. S. Liu¹, P. Banankhah¹, P. A. Genyk¹, P. Kingsford¹, R. R. Chand³, J. P. Li¹, D. Vucicevic⁴, A. S. Vaidya¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. Nattiv¹, S. Hashmi¹, S. Nuno¹, J. Pizula¹, A. E. Lee¹, K. Yang¹, S. Shaw¹, E. DePasquale¹, W. M. Aaron⁵
¹LAC-USC, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴Newark Beth-Israel Medical Center, Newark, NJ, ⁵University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: Some patients with cardiogenic shock require extracorporeal membrane oxygenation (ECMO) for successful bridging to heart transplantation (HT). Herein, we report on the outcomes and…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant
T. J. ONeill IV, G. Jao, A. Kelkar, B. Pisani
Wake Forest Baptist Health System, Winston Salem, NC
*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…
2020 American Transplant Congress
Factors Associated with Renal Graft Loss in Simultaneous Kidney-Heart Transplant Recipients in the UNOS Cohort
K. A. Agarwal¹, H. Patel¹, K. Almonte², F. Cardarelli¹, N. Agrawal¹
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Mount Auburn Hospital, Cambridge, MA
*Purpose: Simultaneous kidney and heart transplants (SKHT) are employed for patients with both end-stage heart failure and severely impaired kidney function. Renal outcomes in such…
2020 American Transplant Congress
Post Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis
G. S. Liu¹, E. C. DePasquale¹, A. M. Wolfson², R. R. Chand³, P. Banankhah¹, J. Nattiv¹, A. D. Salimbangon⁴, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Cardiac sarcoidosis (CS) is a known etiology of end-stage dilated, hypertrophic, or arrhythmogenic cardiomyopathies requiring heart transplantation (HT). We sought to evaluate the long-term…
2020 American Transplant Congress
Investigating the 6-Month Effects of the UNOS Allocation System Changes on the Post Transplant Outcomes in Patients with Hypertrophic Cardiomyopathy
P. Banankhah¹, C. Lum², A. Salimbangon³, G. Liu¹, A. Wolfson⁴, E. DePasquale¹, R. Chand⁵, P. Genyk¹, P. Kingsford¹, J. Li¹, D. Vucicevic⁶, A. Vaidya¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, J. Nattiv¹, S. Hashmi¹, S. Nuno¹, J. Pizula¹, A. Lee¹, K. Yang¹, S. Shah¹
¹Cardiology, University of Southern California, Los Angeles, CA, ²The Queen's Medical Center, Honolulu, HI, ³Cardiology, UCLA Medical Center, Los Angeles, CA, ⁴University of Arizona Sarver Heart Center, Tucson, CA, ⁵Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, ⁶Cardiology, Newark Beth-Israel Medical Center, Newark, NJ
*Purpose: Hypertrophic cardiomyopathy (HCM) has a broad spectrum of presentations. However, the prognosis is poor in patients presenting with significant chamber remodeling, and they often…

« Previous Page
1
…
7
8
9
10
11
…
30
Next Page »